WallStSmart
KRYS

Krystal Biotech Inc

NASDAQ: KRYS · HEALTHCARE · BIOTECHNOLOGY

$312.88
-2.21% today

Updated 2026-06-05

Market cap
$9.37B
P/E ratio
42.57
P/S ratio
22.46x
EPS (TTM)
$7.47
Dividend yield
52W range
$128 – $331
Volume
0.3M

Krystal Biotech Inc (KRYS) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2016201720182019202020212022202320242025
Operating cash flow$-1.31M$-3.89M$-9.45M$-18.71M$-26.08M$-47.94M$-100.57M$-88.80M$123.42M$200.87M
Capital expenditures$15000.00$210000.00$2.23M$6.40M$14.84M$68.34M$52.98M$11.80M$4.24M$11.95M
Depreciation$2000.00$23000.00$141000.00$748000.00$1.85M$2.77M$4.05M$5.01M$6.71M
Stock-based comp$33000.00$246000.00$792000.00$1.24M$3.27M$15.32M$33.23M$39.93M$49.13M$54.51M
Free cash flow$-1.33M$-4.10M$-11.68M$-25.11M$-40.93M$-116.27M$-153.55M$-100.60M$119.18M$188.91M
Investing cash flow$-15000.00$-210000.00$-10.32M$-4.97M$-11.18M$-226.77M$-114.08M$82.64M$-163.44M
Financing cash flow$3.25M$51.77M$73.85M$107.53M$118.02M$347.69M$35.35M$202.75M$27.01M
Dividends paid$0.00
Share repurchases
Debt repayment
Net change in cash$47.67M$83.84M$80.75M$72.98M

Frequently asked questions

What is Krystal Biotech Inc's revenue?

Krystal Biotech Inc's trailing twelve-month revenue is $417.30M, and consensus projects about $1.43T by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is KRYS?

In its most recent fiscal year, KRYS ran a gross margin of 92.61%, an operating margin of 41.45%, and a net margin of 52.64%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does KRYS generate?

KRYS produced $188.91M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is KRYS's balance sheet healthy?

KRYS holds $496.30M in cash and equivalents against — in long-term debt, on $1.22B of shareholder equity. That debt is best read against the cash flow the business throws off each year.